TABLE 4:
Pathways | Total Compound | Hits | Raw p | FDR | Impact |
---|---|---|---|---|---|
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 14 | 1 | 0.17694 | 0.65345 | 0.00399 |
Glycerophospholipid metabolism | 36 | 4 | 0.40972 | 0.65345 | 0.26332 |
Arachidonic acid metabolism | 36 | 1 | 0.46277 | 0.65345 | 0 |
Linoleic acid metabolism | 5 | 1 | 0.46277 | 0.65345 | 0 |
alpha-Linolenic acid metabolism | 13 | 1 | 0.46277 | 0.65345 | 0 |
Biosynthesis of unsaturated fatty acids | 36 | 1 | 0.49008 | 0.65345 | 0 |
Sphingolipid metabolism | 21 | 2 | 0.83211 | 0.88546 | 0.26978 |
Steroid biosynthesis | 42 | 1 | 0.88546 | 0.88546 | 0 |
The table shows the detailed results for pathways relevant to fatostatin treatment. Columns (left to right) denote the pathway names, the total number of compounds in the pathway (Total Compound), the matched number from the lipidomics data (Hits), the original p value calculated from the enrichment analysis (Raw p), the p-value adjusted using False Discovery Rate (FDR), and the pathway impact value calculated from pathway topology analysis (Impact).